Meros Investment Management LP Purchases 299,369 Shares of Harvard Bioscience, Inc. $HBIO

Meros Investment Management LP boosted its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 32.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,217,628 shares of the medical instruments supplier’s stock after acquiring an additional 299,369 shares during the period. Meros Investment Management LP’s holdings in Harvard Bioscience were worth $814,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HBIO. Weber Capital Management LLC ADV bought a new position in Harvard Bioscience in the fourth quarter worth approximately $2,140,000. Nano Cap New Millennium Growth Fund L P bought a new position in Harvard Bioscience in the fourth quarter worth approximately $401,000. Two Sigma Investments LP boosted its holdings in Harvard Bioscience by 139.7% in the third quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 276,372 shares in the last quarter. Strs Ohio bought a new position in Harvard Bioscience in the first quarter worth approximately $117,000. Finally, Essex Investment Management Co. LLC bought a new position in Harvard Bioscience in the fourth quarter worth approximately $124,000. Institutional investors own 80.87% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Benchmark cut their price target on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a report on Friday, March 27th. New Street Research set a $6.00 target price on Harvard Bioscience in a report on Friday, March 13th. Finally, Wall Street Zen lowered Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, March 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $6.00.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $5.99 on Tuesday. Harvard Bioscience, Inc. has a 1 year low of $3.75 and a 1 year high of $9.40. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.99 and a quick ratio of 1.06. The company has a fifty day moving average price of $5.98 and a 200-day moving average price of $6.05. The firm has a market cap of $27.01 million, a price-to-earnings ratio of -2.76 and a beta of 1.53.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Tuesday, May 12th. The medical instruments supplier reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.29. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%. The firm had revenue of $20.76 million for the quarter, compared to analysts’ expectations of $21.20 million.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.